Some diuretics, such as ethacrinic acid and furosemide, have been reported to have a suppressive effect on adenosine 3':5'-cyclic monophosphate (cAMP) production stimulated by antidiuretic hormone (ADH), parathyroid hormone (PTH) and adrenaline (Ebel and Sharp, 1975; Dawborn et al., 1977; Marumo and Mishina, 1978; Thode et al., 1981) , all of which have been generally thought to act on the plasma membrane, activate the receptor-adenylate cyclase complex and produce cyclic mononucleotide as a mediator of these hormonal effects on the respective target cells (Holmegaad, 1982) . These drugs were thought to affect mainly adenylate cyclase activity (Ebel and Sharp, 1975; Dawborn et al., 1977; Marumo and Mishina, 1978) , but another mechanism of action, such as competition with hormonereceptor complex (Abramow, 1974; Thode et al., 1981) , has been postulated. The fact reported by Abramow (1974) that ethacrinic acid and furosemide impair the water permeability response to ADH leads to the speculation that the drug effect on cAMP can extend the final process of cell function so as to suppress it.
In adrenal cells, steroid production stimulated by adrenocorticotropin (ACTH) has also been thought to be mediated by cAMP because both in vivo (Peytremann et al.,1.97313; Espiner et al., 1974) and in vitro (Mackie et al., 1972; Sala et al., 1979) administration of ACTH provoke cAMP increase accompanied with steroid production, and cAMP and its dibutyryl derivative loaded on adrenal cells results in steroid production (Glinsmann et al., 1969; Hayashi et al., 1979) . However, some doubts about the role of cAMP as a mediator of ACTH action (Honn and Chavin, 1977) have remained unresolved, and a mediatory role of calcium (Ca2+) (Yanagibashi, 1979) or guanosine 3':5'-cyclic monophosphate (cGMP) (Glinsmann et al.,1969; Perchellet et al., 1978) has been proposed.
In the present study, the effects of furosemide on ACTH-stimulated corticosterone production and on these possible mediators were investigated using monolayer cultured rat adrenal cells.
It was suggested that furosemide treatment of adrenal cells results in the opposite effects on cAMP-and cGMPmediated processes, suppressing and enhancing the resultant corticosterone production, respectively. semide (Fig. 4) , suggesting that furosemide can act even on the site(s) beyond adenylate cycla se.
Effect of furosemide on cAMP binding to intracellular binding protein It is known that a cAMP-dependent protein kinase has to be functional for ACTH to increase steroidogenesis and that the activation of the protein kinase (Schimmer, 1980) , and the importance of measuring bound cAMP to evaluate the response of added hormone accurately has been stressed (Sala et al., 1979) . In the next experiment, therefore, the extent of the inhibition of the bound cAMP was measured and compared with that of total cAMP. As shown in Fig.  5 , bound cAMP was suppressed in a very similar way to total cAMP. This suggested that the additional furosemide effect may not be on cAMP binding to the regulatory subunit of protein kinase.
Effect of furosemide on Ca2+-dependent corticosterone production stimulated by ACTH The crucial role of Ca2+ in ACTH action (Bowyer and Kitabchi,1974; Yanagibashi, 1979 was prevented by the addition of MIX, and since cAMP released into the medium was also suppressed in a dose-dependent manner similar to that of intracellular cAMP, the furosemide effect could be interpreted as on receptor-adenylate cyclase of adrenal cells. Together with cAMP, corticosterone production was also suppressed, but the changes in both parameters did not closely coincide with each other. cAMP could be suppressed by 10-3M furosemide without any significant effect on corticosterone production. The discrepancy between the changes in cAMP and corticosterone appears to be similar to that in the findings previously reported by several investigators (Sharma et al., 1974; Honn and Chavin, 1977) . i.e., ACTH-stimulated steroid production is revealed even in the phase without cAMP response. This result indicated that the decrease in corticosterone production may not necessarily appear through the reduction of cAMP, suggesting another site(s) of action of furosemide. This appears to be supported by the finding that dbcAMP-stimulated corticosterone production was suppressed by furosemide. The finding that the cAMP bound to its intracellular binding protein was dose-dependently suppressed by furosemide in a very similar pattern to total cAMP indicated that furosemide may not affect the cAMP binding to the regulatory subunit of protein kinase. Next, the mechanisms on cAMP phosphodiesterase and on the step(s) after cAMP binding to protein kinase such as well-known enzyme activities participating in steroid biosynthesis should be considered. However, since furosemide did not affect non-stimulated basal corticosterone, which may be probably produced through the same synthesizing pathway as under ACTH stimulation, the latter possibility might have to be excluded. Rather, it was suggested that furosemide may intensify cAMP phosphodiesterase activity.
The crucial role of Ca2+ in ACTH action has been reported (Bowyer and Kitabchi, 1974; Yanagibashi, 1979) . Accordingly, the effect of furosemide on Ca2+-dependent steroidogenesis was studied.
Though the furosemide effect was also observed when the Ca2+ concentrations in the medium were changed, the magnitude of effectiveness when expressed as a percentage of the control was relatively constant at each Ca2+ concentration. This suggested that Ca2+ action may not be affected by furosemide.
In other words, furosemide may not compete with Ca2+ at any acting site (s).
cGMP has been proposed as another second messenger in adrenal cells by Sharma et al. in their series of studies (Sharma et al., 1974; Sharma, et al., 1976; Perchellet et al., 1978; Perchellet and Sharma, 1979) . Therefore, the effect of furosemide on cGMPmediated processes was studied. In previous reports, cGMP responsiveness to ACTH has been diverse, and lack of responsiveness has also been reported (McMillan et al., 1971; Laychock and Hardman, 1978) .
In our system, a low but significant cGMP increase was detected only at 1250pg/ml.
As a result, 1250pg/ml ACTH-stimulated cGMP production was dose-dependently enhanced by furosemide.
Under 12.5pg/ml ACTH stimulation, this enhancing effect by furosemide was also observed to accompany the decrease in cAMP and corticosterone production, and a mirror-image relatinship between cAMP and cGMP was shown. In addition,dbc GMPstimulated corticosterone production was also enhanced by furosemide. All of these findings were opposite to the results concerning cAMP-mediated processes. This apparent contradiction seems to be similar to the antagonistic action (Estensen et al., 1973) and change (Kuehl et al., 1974; Honn and Chavin, 1975) between cAMP and cGMP, the so-called "Yin Yang hypothesis" (Goldberg et al., 1975) . The cGMP-mediated processes enhanced by furosemide might explain the discrepancy between the changes in cAMP and corticosterone in Fig. 3 
